IP Library › Granted Patent US 10,611,728
Granted Patent B2
US 10,611,728 · App. 16/230,238 · Granted Apr 7, 2020

Isoindoline compositions and methods for treating neurodegenerative disease

Inventors: Gilbert M. Rishton (Los Angeles, CA); Susan M. Catalano (Pittsburgh, PA); Gary C. Look (Santa Clara, CA)
Assignee: COGNITION THERAPEUTICS, INC.
C07D209/44A61K31/4035A61P25/00C07D209/62C07D403/06C07D491/048C07D491/056
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,728
App. No.
16/230,238
Granted
Apr 7, 2020
Kind
B2
Abstract

Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.

Claims (24)

1. A method of treating Alzheimer's disease comprising administering to a subject having said disease a total daily dose of 10 to 2000 mg, of a compound of the Formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the compound is

3. The method of claim 1 wherein the total daily dose is 10 to 300 mg.

4. The method of claim 1 wherein the total daily dose is 20 to 150 mg.

5. The method of claim 1 wherein the total daily dose is administered in a single dose.

6. The method of claim 1 wherein the total daily dose is administered in multiple doses per day.

7. The method of claim 1 wherein the compound is formulated in a capsule or tablet.

8. The method of claim 7 wherein the capsule or tablet comprises 10 to 200 mg of the compound or a pharmaceutically acceptable salt thereof.

9. The method of claim 7 wherein the wherein the total daily dose is 10 to 300 mg.

10. The method of claim 7 wherein the wherein the total daily dose is 20 to 150 mg.

11. The method of claim 1 wherein the compound is administered orally.

12. A method of treating Alzheimer's disease comprising administering to a subject having said disease a pharmaceutical composition comprising a compound of the Formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, wherein a total daily dose of the compound administered is 10 to 2000 mg.

13. The method of claim 12 wherein the compound is

14. The method of claim 12 wherein the total daily dose of the compound administered is 10 to 300 mg.

15. The method of claim 12 wherein the total daily dose of the compound administered is 20 to 150 mg.

16. The method of claim 12 wherein the total daily dose is administered in a single dose.

17. The method of claim 12 wherein the total daily dose is administered in multiple doses per day.

18. The method of claim 12 wherein the pharmaceutical composition is a capsule or tablet.

19. The method of claim 18 wherein the capsule or tablet comprises 10 to 200 mg of the compound or a pharmaceutically acceptable salt thereof.

20. The method of claim 18 wherein the wherein the total daily dose is 10 to 300 mg.

21. The method of claim 18 wherein the wherein the total daily dose is 20 to 150 mg.

22. The method of claim 12 wherein the pharmaceutical composition is administered orally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: RISHTON, GILBERT M.; CATALANO, SUSAN M.; LOOK, GARY C.
To: COGNITION THERAPEUTICS, INC.
Reel/Frame 048728/0983 →
Continuity (4)
Continuation 15700923 · Sep 11, 2017
Continuation 15115187
Provisional Application 61934528 · Jan 31, 2014
Related Publication 20190210966A1 · Jul 11, 2019
Cited By (1)
US 12,466,795